Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 7
2004 2
2005 4
2006 4
2007 7
2008 7
2009 9
2010 5
2011 8
2012 9
2013 14
2014 7
2015 8
2016 11
2017 9
2018 15
2019 11
2020 20
2021 18
2022 9
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Among authors: tak wy. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Cheng AL, et al. Among authors: tak wy. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. Lancet Oncol. 2009. PMID: 19095497 Clinical Trial.
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Bruix J, et al. Among authors: tak wy. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361969 Clinical Trial.
KASL clinical practice guidelines: management of hepatitis C.
Korean Association for the Study of the Liver. Korean Association for the Study of the Liver. Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044763 Free PMC article. Review. No abstract available.
KASL clinical practice guidelines: management of chronic hepatitis B.
Korean Association for the Study of the Liver. Korean Association for the Study of the Liver. Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044762 Free PMC article. Review. No abstract available.
Cell Nuclei Segmentation With Dynamic Token-Based Attention Network.
Khan MS, Ali S, Lee YR, Park SY, Tak WY, Jung SK. Khan MS, et al. Among authors: tak wy. Annu Int Conf IEEE Eng Med Biol Soc. 2023 Jul;2023:1-4. doi: 10.1109/EMBC40787.2023.10340818. Annu Int Conf IEEE Eng Med Biol Soc. 2023. PMID: 38083030
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 Feb 19:S0923-7534(24)00049-8. doi: 10.1016/j.annonc.2024.02.005. Online ahead of print. Ann Oncol. 2024. PMID: 38382875 Free article.
183 results